Selected article for: "protein protein and rna dna"

Author: Biocca, Silvia
Title: Intrabody Expression in Mammalian Cells
  • Cord-id: 1wn7a9j6
  • Document date: 2011_5_6
  • ID: 1wn7a9j6
    Snippet: The intracellular expression of antibodies or antibody fragments (intrabodies) in different compartments of mammalian cells allows to block or modulate the function of endogenous molecules. Intrabodies can alter protein folding, protein-protein, protein-DNA, protein-RNA interactions and protein modification. They can induce a phenotypic knockout and work as neutralizing agents by direct binding to the target antigen, by diverting its intracellular traffic or by inhibiting its association with bi
    Document: The intracellular expression of antibodies or antibody fragments (intrabodies) in different compartments of mammalian cells allows to block or modulate the function of endogenous molecules. Intrabodies can alter protein folding, protein-protein, protein-DNA, protein-RNA interactions and protein modification. They can induce a phenotypic knockout and work as neutralizing agents by direct binding to the target antigen, by diverting its intracellular traffic or by inhibiting its association with binding partners. They have been largely employed as research tools and are emerging as therapeutic molecules for the treatment of human diseases as viral pathologies, cancer and misfolding diseases. The fast growing bio-market of recombinant antibodies provides intrabodies with enhanced binding specificity, stability and solubility, together with lower immunogenicity, for their use in therapy. This chapter describes the crucial aspects required to express intrabodies in different intracellular compartments of mammalian cells, their various modes of action and gives an update on the applications of intrabodies in human diseases.

    Search related documents:
    Co phrase search for related documents
    • aberrant expression and ad disease: 1, 2, 3, 4
    • aberrant expression and long terminal: 1
    • aberrant expression and long terminal repeat: 1
    • aberrant expression and low toxicity: 1
    • aberrant expression and lymphoma cell: 1
    • action mode and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • action mode and adp ribosylation: 1
    • action mode and low toxicity: 1, 2, 3, 4